Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Apr 6;7(1):e001226.
doi: 10.1136/openhrt-2019-001226. eCollection 2020.

Incidence, treatment and mortality of new-onset atrial fibrillation patients at the intensive care unit

Affiliations
Comparative Study

Incidence, treatment and mortality of new-onset atrial fibrillation patients at the intensive care unit

Maartje S Jacobs et al. Open Heart. .

Abstract

Objective: Critically ill patients admitted to the intensive care unit (ICU) often develop atrial fibrillation (AF), with an incidence of around 5%. Stroke prevention in AF is well described in clinical guidelines. The extent to which stroke prevention is prescribed to ICU patients with AF is unknown. We aimed to determine the incidence of new-onset AF and describe stroke prevention strategies initiated on the ICU of our teaching hospital. Also, we compared mortality in patients with new-onset AF to critically ill patients with previously diagnosed AF and patients without any AF.

Methods: This study was a retrospective cohort study including all admissions to the ICU of the Martini Hospital (Groningen, The Netherlands) in the period 2011 to 2016. Survival analyses were performed using these real-world data.

Results: In total, 3334 patients were admitted to the ICU, of whom 213 patients (6.4%) developed new-onset AF. 583 patients (17.5%) had a previous AF diagnosis, the other patients were in sinus rhythm. In-hospital mortality and 1-year mortality after hospital discharge were significantly higher for new-onset AF patients compared with patients with no history of AF or previously diagnosed AF. At hospital discharge, only 56.3% of the new-onset AF-patients eligible for stroke prevention received an anticoagulant. Anticoagulation was not dependent on CHA2DS2-VASc score or other patient characteristics. An effect of anticoagulative status on mortality was not significant.

Conclusion: AF is associated with increased mortality in critically ill patients admitted to the ICU. More guidance is needed to optimise anticoagulant treatment in critically ill new-onset AF patients.

Keywords: anticoagulation; atrial fibrillation; critical illness; mortality; new-onset.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MJ is an employee of Sanofi. The work presented here is not related to this employment and presents a personal opinion in the context of PhD research. RGT reports grants and personal fees from Boehringer Ingelheim, personal fees from Bayer and personal fees from Pfizer/Bristol Meyer Squibb all outside the submitted work. MJP reports grants and personal fees from various pharmaceutical industries all outside the submitted work. MJP holds stocks in Ingress Health and Pharmacoeconomics Advice Groningen (PAG Ltd).

Figures

Figure 1
Figure 1
Survival censored at 360 days of follow-up after hospital discharge for all patients (n=3334), stratified by all atrial fibrillation category. A vertical line in the curve represents a censored patient. AF, atrial fibrillation.
Figure 2
Figure 2
Survival censored at 360 days of follow-up after hospital discharge compared with propensity score matched groups of patients with no atrial fibrillation or known atrial fibrillation or versus patients with new-onset atrial fibrillation (n=208, n=195 and n=213, respectively). A vertical line in the curve represents a censored patient. AF, atrial fibrillation.

Similar articles

Cited by

References

    1. Kirchhof P, Benussi S, Kotecha D, et al. . 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–962.10.1093/eurheartj/ehw210 - DOI - PubMed
    1. Lip GYH, Laroche C, Popescu MI, et al. . Improved outcomes with European Society of cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General pilot registry. Europace 2015;17:1777–86.10.1093/europace/euv269 - DOI - PubMed
    1. Darwish OS, Strube S, Nguyen HM, et al. . Challenges of anticoagulation for atrial fibrillation in patients with severe sepsis. Ann Pharmacother 2013;47:1266–71.10.1177/1060028013500938 - DOI - PubMed
    1. Yoshida T, Fujii T, Uchino S, et al. . Epidemiology, prevention, and treatment of new-onset atrial fibrillation in critically ill: a systematic review. J Intensive Care 2015;3:1–11.10.1186/s40560-015-0085-4 - DOI - PMC - PubMed
    1. Bosch NA, Cimini J, Walkey AJ. Atrial fibrillation in the ICU. Chest 2018;154:1424–34.10.1016/j.chest.2018.03.040 - DOI - PMC - PubMed

Publication types

MeSH terms